The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck.
 
Matthew H. Taylor
Honoraria - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Trillium Therapeutics
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Onyx; Trillium Therapeutics
Speakers' Bureau - Eisai
 
Drew W. Rasco
Employment - START
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; TaiRx, Inc.
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Birdie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Rexahn Pharmaceuticals (Inst); Santa Maria Biotherapeutics (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Asana Biosciences
 
Marcia S. Brose
Honoraria - Bayer
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Genzyme; Loxo; Novartis
Research Funding - Bayer (Inst); Blueprint Medicines (Inst); Eisai (Inst); Exelixis (Inst); Loxo (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Pfizer; UpToDate
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Caris Life Sciences; Fujifilm; Genentech/Roche; HERON; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Sanofi
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; US Oncology
 
Stephen Lane Richey
Employment - Texas Oncology
Leadership - Texas Oncology
Consulting or Advisory Role - Exelixis; Prometheus; Sanofi
Research Funding - Abbvie; Acerta Pharma; Aptiv Solutions; Bayer Schering Pharma; Biothera; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Celgene; Cerulean Pharma; Daiichi Sankyo; Dendreon; Eisai; Genentech/Roche; Gilead Sciences; GlaxoSmithKline/Novartis; HUYA Bioscience International; ImClone Systems; Immunomedics; Janssen Oncology; Lilly; MedImmune; Merck; Merck; Merrimack; Nektar; Novartis; Oncolytics; Oncothyreon; Pharm-Olam; RTOG; Seagen; US Oncology
 
Allen Lee Cohn
Honoraria - Bristol-Myers Squibb; Ipsen; Merrimack; Roche/Genentech
Speakers' Bureau - Merrimack
 
Donald A. Richards
Consulting or Advisory Role - Boehringer Ingelheim; Insys Therapeutics; IntegraGen; Lilly; Merrimack; Pharmacyclics
Speakers' Bureau - Celgene
 
Daniel E. Stepan
Employment - Eisai
 
Corina E. Dutcus
Employment - Eisai
Leadership - Eisai
Research Funding - Eisai (Inst)
 
Matthew Guo
Employment - Eisai
 
Robert Charles Shumaker
Employment - Asubio Pharma (I); Eisai
 
Emmett V. Schmidt
Employment - Merck
Stock and Other Ownership Interests - Merck; Merck (I)
 
Lori J. Wirth
Consulting or Advisory Role - Amgen; Blueprint Medicines; Eisai; Loxo; Merck; Novartis